INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 46 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $10,935,000 | -18.9% | 13,500,000 | -25.0% | 0.38% | -41.9% |
| Q2 2020 | $13,479,000 | -8.5% | 18,000,000 | 0.0% | 0.65% | -37.6% |
| Q1 2020 | $14,732,000 | -9.1% | 18,000,000 | +12.5% | 1.04% | +76.0% |
| Q4 2019 | $16,205,000 | +17.6% | 16,000,000 | 0.0% | 0.59% | +31.3% |
| Q3 2019 | $13,775,000 | -4.5% | 16,000,000 | 0.0% | 0.45% | +6.1% |
| Q2 2019 | $14,420,000 | +21.2% | 16,000,000 | +33.3% | 0.42% | -33.6% |
| Q1 2019 | $11,895,000 | -11.9% | 12,000,000 | -18.0% | 0.64% | +7.4% |
| Q4 2018 | $13,509,000 | -8.5% | 14,636,000 | 0.0% | 0.60% | +93.8% |
| Q3 2018 | $14,768,000 | +23.6% | 14,636,000 | +7.3% | 0.31% | -31.0% |
| Q2 2018 | $11,946,000 | -42.6% | 13,636,000 | -47.4% | 0.44% | -20.0% |
| Q1 2018 | $20,796,000 | +101.0% | 25,912,000 | +100.0% | 0.56% | +105.9% |
| Q4 2017 | $10,348,000 | – | 12,956,000 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SILVERBACK ASSET MANAGEMENT LLC | 12,851,000 | $12,016,000 | 2.95% |
| Context Capital Management, LLC | 3,000,000 | $2,804,000 | 2.24% |
| Man Investments (CH) AG | 3,000,000 | $2,798,000 | 1.76% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 42,500,000 | $39,540,000 | 1.52% |
| MACKAY SHIELDS LLC | 17,069,000 | $15,982,000 | 0.73% |
| HIGHFIELDS CAPITAL MANAGEMENT LP | 73,035,000 | $68,425,000 | 0.63% |
| WOLVERINE ASSET MANAGEMENT LLC | 42,307,000 | $39,554,000 | 0.61% |
| LINDEN ADVISORS LP | 14,122,000 | $13,194,000 | 0.49% |
| GLG LLC | 9,100,000 | $8,486,000 | 0.47% |
| Jabre Capital Partners S.A. | 3,400,000 | $3,179,000 | 0.38% |